The First 68Ga-FAPI46 PET-CT Imaging in Turkey!..

The first 68Ga-FAPI46 PET-CT imaging in Turkey was carried out with the collaboration of Hamidiye Faculty of Pharmacy, University of Health Sciences and Başakşehir Çam-Sakura City Hospital, Ministry of Health.

The first 68Ga-FAPI46 PET-CT imaging in Turkey was carried out with the collaboration of Hamidiye Faculty of Pharmacy, University of Health Sciences and Başakşehir Çam-Sakura City Hospital, Ministry of Health. 

The first 68Ga-FAPI46 PET-CT imaging was performed in a research conducted under the direction of Assoc. Prof. Dr. Burçak Yılmaz (Nuclear Medicine Clinic, Başakşehir Çam-Sakura City Hospital), Assoc. Prof Dr. Nilüfer Bulut (Medical Oncology Department, Başakşehir Çam-Sakura City Hospital) and Assoc. Prof. Dr. Güldem Mercanoğlu (Department of Pharmacology, Hamidiye Pharmacy Faculty) which aimed at evaluating the effectiveness of neoadvujan therapy in oncological indications. 

PET-CT imaging performed with 68Ga-labeled compounds is used to determine the extent of the disease and to evaluate effective treatment alternatives and treatment response by enabling high-sensitivity molecular imaging in many oncological indications, especially in neuroendocrine tumors and prostate cancer. Recently, developed fibroblast activation protein inhibitors (FAPIs) labeled with 68Ga have shown promising results in preclinical studies. Data from a small number of clinical studies have indicated that they may be superior to 18F-Fluorodeoxyglucose (18F-FDG) in screening cancers, such as breast, colon and prostate that overexpress fibroblast activation protein (FAP). In the study conducted at the Nuclear Medicine Clinic of Başakşehir Çam-Sakura City Hospital, the first 68Ga-FAPI46 PET-CT imaging was performed. 

15-12-2020